Savara Inc (SVRA) stock is experiencing a significant pre-market surge of 6.32% following a series of positive analyst actions. The biotechnology company has received multiple upgrades and price target increases, boosting investor confidence ahead of the market open.
H.C. Wainwright has made a notable upgrade, raising their rating on Savara from Neutral to Buy. Analyst Andrew Fein has also significantly increased the price target from $2 to $5, citing improved resubmission prospects for the company. Simultaneously, Oppenheimer has raised its price target on Savara from $5 to $6, while maintaining an Outperform rating.
These bullish moves from analysts reflect growing optimism about Savara's potential. According to FactSet, the company now has an average rating of Buy and a mean price target of $7.93. The pre-market rally suggests that investors are responding positively to these upward revisions, potentially anticipating stronger performance from Savara in the near future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。